Combined Treatment with Anticancer Vaccine Using Genetically Modified Endothelial Cells and Imatinib in Bladder Cancer
하승범, 박용현, 이은혜, 구자현, 김현회, 곽철,
소속 상세정보
하승범 ( Ha Seung-Beom )
Seoul National University College of Medicine Department of Urology
박용현 ( Park Yong-Hyun )
Seoul National University College of Medicine Department of Urology
이은혜 ( Lee Eun-Hye )
Seoul National University College of Medicine Department of Urology
구자현 ( Ku Ja-Hyeon )
Seoul National University College of Medicine Department of Urology
김현회 ( Kim Hyeon-Hoe )
Seoul National University College of Medicine Department of Urology
곽철 ( Kwak Cheol )
Seoul National University College of Medicine Department of Urology
KMID : 0358320110520050327
Abstract
Purpose: We sought to maximize the antitumor effect of an anticancer vaccine based on genetically modified endothelial cells by combining it with the platelet-derived growth factor receptor inhibitor imatinib.
Materials and Methods: Human umbilical vein endothelial cells (HUVECs) were infected with 10 MOI of Ad-CMV-mGMCSF to make anticancer vaccines. One million mouse bladder cancer cells (MBT-2) were subcutaneously inoculated in C3H mice. The experimental groups included the following: Group 1 (phosphate-buffered saline), Group 2 (anticancer vaccine and GM-CSF), Group 3 (imatinib), and Group 4 (anticancer vaccine, GM-CSF, and imatinib). Tumor growth and body weight were measured weekly. At 4 weeks, the tumors were immunostained with anti-CD31, and microvessel density (MVD) was measured. To evaluate the immunological mechanism of each treatment, flow cytometry analysis of activated CD4 and CD8 cells was performed.
Results: At 4 weeks, the mean body weight of each group, excluding the extracted tumor weight, was not significantly different. Since week 3, the mean tumor volume in Group 4 was the smallest among the treatment groups (p<0.05), and a synergistic suppressive effect on tumor volume was observed in Group 4. The MVD in Group 4 was the most suppressed among the treatment groups (p<0.05), and a synergistic anti-angiogenic effect was observed. Flow cytometry analysis revealed that activated CD4+ and CD8+ cells increased in Group 2 and decreased in Group 3 compared with the other groups.
Conslusions: The combination of genetically modified endothelial cell vaccines and imatinib showed a synergistic antiangiogenic effect in bladder cancer.
키워드
Immunotherapy; Platelet-derived growth factor; Urinary bladder neoplasms
원문 및 링크아웃 정보
등재저널 정보